

# Comments on a Randomized Parallel Non-inferiority Trial to Evaluate the Safety and Efficacy of Levetiracetam in Comparison to Magnesium Sulfate in the Management of Severe Preeclampsia

Srinivasan Parthasarathy

Received on: 09 August 2022; Accepted on: 15 January 2023; Published on: 11 May 2023

**Keywords:** Eclampsia, Pregnancy induced hypertension, Premonitory symptoms.

*Journal of South Asian Federation of Obstetrics and Gynaecology* (2023); 10.5005/jp-journals-10006-2216

## Dear Editor,

I read with interest the article on the role of Levetiracetam in the prevention of eclampsia. I have a few clarifications with regard to the article titled "A Randomized Parallel Non-inferiority Trial to Evaluate the Safety and Efficacy of Levetiracetam in Comparison to Magnesium Sulfate in the Management of Severe Preeclampsia".<sup>1</sup>

The outcome measure and the necessity to remain the same or increase in the method of calculating sample size is unclear. The incidence of eclampsia in a case of severe preeclampsia is only 2–3% according to textbooks. Therefore, this problem is likely to escape and may prove to be inconsequential with the study sample of a total of 60. In such sample size studies, the authors could have used control to find out the real use. The authors have mentioned that there is a significant difference between the blood pressures of both groups on admission. This will lead to misinterpretation of results. There is a mention in Table 5 that the systolic blood pressure is 1133!!

What was the time duration between drug administration and delivery? Will it not change neonatal outcomes?

There are a lot of published studies on these issues.<sup>2,3</sup>

I request the authors to clarify on these issues for the benefit of readers.

## REFERENCES

1. Yaliwal RG, Biradar AM, Bhagavati SB, et al. A Randomized parallel non-inferiority trial to evaluate the safety and efficacy of levetiracetam

---

Department of Anaesthesiology, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth, Puducherry, India

**Corresponding Author:** Srinivasan Parthasarathy, Department of Anaesthesiology, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth, Puducherry, India, Phone: +91 9443142582, e-mail: painfreepartha@gmail.com

**How to cite this article:** Parthasarathy S. Comments on a Randomized Parallel Non-inferiority Trial to Evaluate the Safety and Efficacy of Levetiracetam in Comparison to Magnesium Sulfate in the Management of Severe Preeclampsia. *J South Asian Feder Obst Gynae* 2023;15(2):265.

**Source of support:** Nil

**Conflict of interest:** None

---

in comparison to magnesium sulfate in the management of severe preeclampsia. *J South Asian Feder Obst Gynae* 2022;14(3):287–291. DOI: 10.5005/jp-journals-10006-2046.

2. Anshu, Deepika. Maternal and perinatal outcome in severe pre-eclampsia and eclampsia. *J South Asian Feder Obs Gynae* 2009;1(3):25–28. DOI: 10.5005/jp-journals-10006-1005.
3. Vaishnav SB, Raithatha N, Kathawadia K, et al. Making magnesium sulfate therapy safer in eclampsia: A comparative study of zuspan regime vs low-dose intravenous MgSO<sub>4</sub> regime. *J South Asian Feder Obst Gynae* 2019;11(2):126–130. DOI: <https://doi.org/10.5005/jp-journals-10006-1675>.